Apyx Medical Corporation (APYX) News

Apyx Medical Corporation (APYX): $3.59

0.19 (+5.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter APYX News Items

APYX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

APYX News Highlights

  • For APYX, its 30 day story count is now at 5.
  • Over the past 22 days, the trend for APYX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about APYX are LI, UL and DRUG.

Latest APYX News From Around the Web

Below are the latest news stories about APYX MEDICAL CORP that investors may wish to consider to help them evaluate APYX as an investment opportunity.

Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

CLEARWATER, Fla., February 01, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced it has submitted a 510(k) premarket notification ("510(k) submission") for the Renuvion APR Handpiece to the U.S. Food and Drug Administration ("FDA"), supported by a clinical study and real-world evidence. The 510(k) submission is intended to expand Renuvion’s indications for use

Yahoo | February 1, 2023

Recent uptick might appease Apyx Medical Corporation (NASDAQ:APYX) institutional owners after losing 72% over the past year

If you want to know who really controls Apyx Medical Corporation ( NASDAQ:APYX ), then you'll have to look at the...

Yahoo | January 27, 2023

APYX MEDICAL CORPORATION LAUNCHES NEW 'APYX ONE CONSOLE' FOR COSMETIC SURGICAL PROCEDURES IN THE UNITED STATES

Apyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of its latest-generation Renuvion generator, the Apyx One Console, in the United States.

Yahoo | January 25, 2023

Apyx Medical narrows FY revenue guidance, guides Q4 and FY revenue outlook below estimates

  • Apyx Medical (NASDAQ:APYX) has reported preliminary revenue results for the Q4 and FY22.
  • Q4 total revenue is anticipated to be in a range of $12.1M to $12.5M, representing a decline of 28% to 26% Y/Y, vs consensus of $13.36M.
  • Q4 Advance...

    Seeking Alpha | January 10, 2023

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

CLEARWATER, Fla., January 10, 2023--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2022.

Yahoo | January 10, 2023

APYX® MEDICAL CORPORATION EMBARKS ON INAUGURAL BRAND CAMPAIGN FOR RENUVION®

Apyx® Medical Corporation (NASDAQ: APYX), the manufacturer of Renuvion®, a proprietary helium plasma and radiofrequency technology, today announces the launch of its first-ever direct-to-consumer brand campaign. Entitled #ThisIsMe, the campaign is aimed at U.S. consumers who are interested in a minimally invasive procedure with the Renuvion technology.

Yahoo | January 3, 2023

Apyx Medical Corporation to Participate in the Piper Sandler 34th Annual Healthcare Conference

CLEARWATER, Fla., November 22, 2022--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Piper Sandler 34th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY. Management will participate in fireside chat on Wednesday, November 30 at 11:00 a.m. ET.

Yahoo | November 22, 2022

Apyx Medical Third Quarter 2022 Earnings: Misses Expectations

Apyx Medical ( NASDAQ:APYX ) Third Quarter 2022 Results Key Financial Results Revenue: US$9.11m (down 23% from 3Q...

Yahoo | November 12, 2022

Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Apyx Medical (APYX) and Phathom Pharmaceuticals (PHAT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB – Research Report), Apyx Medical (APYX – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report). Biogen (BIIB) In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen, with a price target of $325.00. The company's shares closed last Thursday at $289.77, close to its 52-week high of $292.45. According to TipRanks.

Catie Powers on TipRanks | November 10, 2022

Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates

Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5627 seconds.